An interventional study of TEAS and sham TEAS in Quality of Life and Chronic Cancer Pain, sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-30.
Sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Cancer Pain with a site in China — 13 open to participants now, 13 under way, 1 of them phase 3. Cancer Pain · China.
Among the 31 studies in Cancer Pain with a site in China, this one is the 3rd largest by planned enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2025, is one of 12 with no phase, reaches primary completion later than 4 of the 12 other live ones, and was the 23rd registered.
311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.
Browse Cancer Pain studies →13 of the 31 studies in Cancer Pain with a site in China are open now. Recruiting first, the newest first:
Qinghai Red Cross Hospital · Sites in China
Ages 18–80
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–75
Taian Cancer Hospital · Sites in China
Ages 65+
Tongji Hospital · Sites in China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 45 Cancer Pain studies recruiting now, 33 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 6 · Phase 4 1
First in 2012; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 290 is above the median of 63 across 236 interventional studies indexed under Cancer Pain.
Median enrollment 110 across the 24 interventional studies, 200 across the 7 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 31 have an industry lead sponsor. The 10 most frequent:
The Third Affiliated hospital of Zhejiang Chinese Medical University is the lead sponsor of 45 studies on the registry; 25 are open to participants now.
The Third Affiliated hospital of Zhejiang Chinese Medical University has 2 studies filed under Cancer Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Cancer Pain with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07657390Cancer Institute and Hospital, Chinese Academy of Medical SciencesProspective Randomized Controlled Clinical Study of Acupoint Application With Gutong Plaster in the Treatment of Moderate to Severe Cancer Pain | 2026-12-31 |
| NCT07869797Mundipharma (China) Pharmaceutical Co. LtdReal-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer Patients | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies in Cancer Pain with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to objectively evaluate the effect of Patient-Controlled Transcutaneous Electrical Acupoint Stimulation (PC-TEAS) on improving the quality of life in patients with chronic cancer pain, thereby providing evidence-based medical support for its efficacy and offering practical basis for patients to achieve home-based auxiliary treatment based on their own needs. Furthermore, by observing and comparing changes in indicators such as pain-related scores, analgesic consumption, emotional scores, spontaneous bowel movements, and adverse events, this research will comprehensively assess the advantages of PC-TEAS in the management of chronic cancer pain and explore other potential benefits of this intervention for patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First, acupoint group ① (bilateral Hegu \[LI4\] and Neiguan \[PC6\]) received 30 minutes of transcutaneous electrical acupoint stimulation (TEAS), followed by acupoint group ② (bilateral Sanyinjiao \[SP6\] and Zusanli \[ST36\]) for the same duration.
Other: TEAS
Except for the transcutaneous acupoint electrical stimulator, which has no current output, the other operations are the same as TEAS Intervention Group.
Other: sham TEAS
Patients assumed a supine or sitting position, and after routine skin disinfection at the acupoint sites, one pair of electrode patches was attached to the two ipsilateral acupoints of the same group, with the same procedure performed on the contralateral side. A transcutaneous electrical acupoint stimulator was used to apply TEAS sequentially to acupoint groups ① and ②. Each acupoint group received a single TEAS session lasting 30 minutes. Participants were permitted to undergo multiple TEAS sessions within the same day, with all treatments recorded in a pain diary. The TEAS parameters were set as a continuous wave at a frequency of 2 Hz, with the current intensity adjusted to the patient's tolerance level. The treatment followed a "patient-controlled, as-needed" administration pattern. Each treatment course lasted 7 days, with a minimum of 3 treatment days per course and a total of no fewer than 5 sessions per course. A total of 4 treatment courses were conducted.
Participants were informed that, due to individual variations in sensory thresholds, it is normal if no distinct sensation is perceived even at the maximum stimulation intensity. Regardless of subjective perception, the transcutaneous electrical acupoint stimulation treatment remains active and exerts its therapeutic effects continuously.
The area under the curve (AUC) of the FACT-G (Functional Assessment of Cancer Therapy - General) total score for assessing quality of life in patients with chronic cancer pain after 4 weeks of treatment.
the FACT-G comprises 27 items grouped into 4 domains: physical well-being, social/family well-being, emotional well-being, and functional well-being; some items require reverse scoring, with the total score ranging from 0 to 108. Higher scores indicate better quality of life. Using the area under the curve scoring method allows for the observation of the cumulative benefit of PC-TEAS usage in patients over the entire treatment period
Time frame: Baseline; Week 1; Week 2; Week 3;Week 4; Week 8; Week 12
the changes in BPI score from baesline
The Brief Pain Inventory (BPI) is primarily used to assess pain severity and its multidimensional impact on patients' quality of life. The scale consists of two core components: BPI-S (Pain Severity) and BPI-I (Pain Interference). The BPI-S quantifies the severity of pain through four items: average pain, worst pain, least pain, and current pain intensity. The BPI-I evaluates the degree to which pain interferes with daily functioning across seven domains: mobility, activities of daily living, work, sleep, relationships with others, enjoyment of life, and mood, thereby providing a comprehensive multidimensional reflection of pain's impact on patient quality of life.Scores range from 0-10, with higher scores indicating more severe pain
Time frame: Baseline; Week 4; Week 8; Week 12
Dosage of analgesics used on the assessment days
Changes in the amount of analgesic use from baseline
Time frame: Baseline; Week 4; Week 8 ; Week 12
Spontaneous bowel movements (SBM) during assessment days
Spontaneous bowel movements (SBM) refer to bowel movements that occurred in the past 24 hours without the use of rescue laxatives. The number of spontaneous bowel movements by the subjects in the past week was recorded.
Time frame: Baseline; Week 4; Week 8; Week 12
Bowel Function Index (BFI) during assessment days
The Bowel Function Index (BFI) is a clinical tool specifically designed to assess opioid-induced constipation. It records the patient's ratings over the past week for straining during defecation, sense of incomplete bowel evacuation, and overall satisfaction with the bowel movement process.
Time frame: Baseline; Week 4; Week 8; Week 12
The changes in mood scale scores of Hamilton Depression Rating Scale (HAMD) on the assessment days
The Hamilton Depression Rating Scale (HAMD) is used to assess depressive. The HAMD serves as a standard clinical instrument for evaluating depressive states, In this study, participants' HAMD-17 total scores were recorded to observe changes from baseline.
Time frame: Baseline; Week 4; Week 8;Week 12
The changes in mood scale scores of Hamilton Anxiety Scale (HAMA) on the assessment days
The Hamilton Anxiety Scale (HAMA) is used to assess anxiety symptoms, The HAMA provides an important basis for diagnosing anxiety disorders and grading their severity. In this study, participants' HAMA scores were recorded to observe changes from baseline.
Time frame: Baseline; Week 4; Week 8; Week 12
Frequency of breakthrough pain in the week preceding the assessment days
The frequency of breakthrough pain episodes, along with the types and doses of rescue medication used in the preceding week, were recorded.
Time frame: Baseline; Week 4;Week 8; Week 12
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2025 (actual). Primary completion is estimated for Oct 2026, 13 months after the start.
Of 73 non-industry interventional studies with no phase under Cancer Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 13 months is below that.
Counting every sponsor, half of 76 studies reached it within 18 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Third Affiliated hospital of Zhejiang Chinese Medical University